C4orf47 contributes to the dormancy of pancreatic cancer under hypoxic conditions.
dormancy
hypoxia
pancreatic cancer
Journal
Journal of Cancer
ISSN: 1837-9664
Titre abrégé: J Cancer
Pays: Australia
ID NLM: 101535920
Informations de publication
Date de publication:
2023
2023
Historique:
received:
16
09
2022
accepted:
12
12
2022
entrez:
6
2
2023
pubmed:
7
2
2023
medline:
7
2
2023
Statut:
epublish
Résumé
In our comprehensive analysis of pancreatic cancer pathology, we found that the C4orf47 molecule was upregulated in hypoxic environments. C4orf47 is reported to be a centrosome-associated protein, but its biological significance in cancer is completely unknown; therefore, we assessed its role in pancreatic cancer. We found that C4orf47 was a direct target of HIF-1α and is upregulated in hypoxic conditions, in which it suppressed the cell cycle and inhibits cell proliferation through up-regulation of the cell cycle repressors Fbxw-7, P27, and p57; and the down-regulation of the cell cycle promoters c-myc, cyclinD1, and cyclinC. Furthermore, C4orf47 induced epithelial-mesenchymal transition and enhanced their cell plasticity and invasiveness. In addition, the p-Erk/p-p38 ratio was significantly enhanced and down-regulated CD44 expression by C4orf47 suppression, suggesting that C4orf47 is involved in pancreatic cancer dormancy under hypoxic conditions. Furthermore, the potential of C4orf47 expression was a good prognostic biomarker for pancreatic cancer. These results contribute to the elucidation of the pathology of refractory pancreatic cancer and the development of novel therapeutic strategies.
Identifiants
pubmed: 36741255
doi: 10.7150/jca.78993
pii: jcav14p0306
pmc: PMC9891878
doi:
Types de publication
Journal Article
Langues
eng
Pagination
306-317Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):919-22
pubmed: 11072146
Cancer Lett. 2020 Aug 1;484:9-15
pubmed: 32380129
Mol Med Rep. 2014 Nov;10(5):2495-504
pubmed: 25119644
Mol Biol Cell. 2014 Sep 15;25(18):2677-81
pubmed: 25213191
Adv Anat Pathol. 2012 Nov;19(6):351-62
pubmed: 23060061
Ann Surg. 2003 Jan;237(1):74-85
pubmed: 12496533
Nat Rev Cancer. 2004 Jun;4(6):437-47
pubmed: 15170446
Br J Cancer. 2010 Feb 16;102(4):738-47
pubmed: 20087349
Nat Rev Cancer. 2004 Apr;4(4):253-65
pubmed: 15057285
Cancer Lett. 2018 Jul 1;425:164-173
pubmed: 29605511
J Exp Clin Cancer Res. 2018 Jul 27;37(1):173
pubmed: 30053872
Front Oncol. 2018 Sep 12;8:381
pubmed: 30258818
Genes Dev. 2005 Mar 15;19(6):756-67
pubmed: 15769947
Cell Stem Cell. 2011 Sep 2;9(3):262-71
pubmed: 21885021
Cancer Sci. 2019 Feb;110(2):474-480
pubmed: 30575231
Biochim Biophys Acta. 2015 May;1849(5):506-16
pubmed: 24704206
J Cell Sci. 2014 Oct 1;127(Pt 19):4128-33
pubmed: 25074808
Nature. 2015 Nov 26;527(7579):525-530
pubmed: 26560028
Cell. 2004 Apr 16;117(2):239-51
pubmed: 15084261
Cancer Lett. 2016 Feb 28;371(2):143-50
pubmed: 26655998
Cancer Lett. 2016 Apr 28;374(1):44-53
pubmed: 26797459
Mol Biol Cell. 2001 Apr;12(4):863-79
pubmed: 11294892
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
J Cancer. 2020 Feb 10;11(8):2289-2302
pubmed: 32127956
Mol Cancer Ther. 2008 Nov;7(11):3480-9
pubmed: 18974392
EMBO J. 2004 May 19;23(10):2116-25
pubmed: 15103331
J Biol Chem. 1999 May 14;274(20):13886-93
pubmed: 10318797
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Mol Oncol. 2016 Oct 7;11(1):62-78
pubmed: 28017284
Cancer Res. 2008 May 1;68(9):3260-8
pubmed: 18451152
World J Gastroenterol. 2015 Apr 7;21(13):3876-87
pubmed: 25852272
Cancer Biol Ther. 2006 Jul;5(7):729-35
pubmed: 16861922
Ann Surg Oncol. 2009 Dec;16(12):3316-22
pubmed: 19707831
Cell Immunol. 2013 Mar;282(1):9-16
pubmed: 23639351
Cancer Res. 2003 Apr 1;63(7):1684-95
pubmed: 12670923
Methods Mol Biol. 2018;1686:49-57
pubmed: 29030811
Anticancer Res. 2017 Dec;37(12):6649-6654
pubmed: 29187440
Oncol Rep. 2022 May;47(5):
pubmed: 35315500
Toxicol Sci. 2013 Apr;132(2):379-89
pubmed: 23161664
Cell. 2012 Jan 20;148(1-2):349-61
pubmed: 22265420
Cancer Res. 2015 Jan 1;75(1):111-9
pubmed: 25385028
Cell Mol Life Sci. 2017 Aug;74(15):2761-2771
pubmed: 28331999
Oncotarget. 2016 Nov 1;7(44):71362-71377
pubmed: 27655685
Biochem Pharmacol. 2019 Apr;162:169-176
pubmed: 30414937
Ann Surg. 2011 Aug;254(2):311-9
pubmed: 21606835
Front Oncol. 2018 Nov 05;8:505
pubmed: 30456206
Ann Surg Oncol. 2019 May;26(5):1528-1534
pubmed: 30868514
J Cell Biochem. 2013 May;114(5):967-74
pubmed: 23225225
Cancer Sci. 2014 Mar;105(3):272-80
pubmed: 24438533
Int J Oncol. 2001 Oct;19(4):827-32
pubmed: 11562762
Cancer Res. 2017 Dec 15;77(24):6851-6862
pubmed: 29038348
Cancer Cell. 2013 Mar 18;23(3):347-61
pubmed: 23518349
Int J Mol Sci. 2021 Mar 18;22(6):
pubmed: 33803555
J Natl Cancer Inst. 2001 Feb 21;93(4):266-76
pubmed: 11181773
Science. 2000 Mar 10;287(5459):1804-8
pubmed: 10710306